Paris (France), 31st August 2018 – Servier, an independent international pharmaceutical company, announced today that it has finalized the previously announced acquisition of Shire’s oncology branch after obtaining regulatory clearance. The 2.4 billion dollar transaction will enable Servier to establish a direct commercial presence in the United States and strengthen its oncology drug portfolio in the countries in which the Group is already present.
“This acquisition is a major step in achieving the Servier group’s ambition”, declared Olivier Laureau, President of Servier. “It marks the launch of Servier’s commercial activities in the world’s largest pharmaceutical market – the United States – and significantly strengthens its portfolio of oncology drugs. It is part of Servier’s twofold strategy: to continue to treat an increasing number of patients with innovative medications across the world and become a world reference in oncology.”
In the United States, Servier products will be marketed by the Group’s new subsidiary, Servier Pharmaceuticals LLC (Boston), which is made up of 80 people, including those employees transitioning from Shire to Servier. Servier Pharmaceuticals will be led by David K. Lee who previously led Shire’s Global Genetic Diseases and Oncology franchises. The subsidiary will continue to market ONCASPAR® in the United States. Servier Pharmaceuticals’ twofold aim is to develop a strong sales presence in the United States, based on Servier’s existing portfolio, and to enrich the portfolio with close-to-market or marketed innovative products, in accordance with the Group’s strategy.
Outside the United States, approximately 75 employees from Shire are expected to integrate into Servier’s organizational structure. They will continue to market ONCASPAR® and ONIVYDE® according to local legislation.
With this acquisition, Servier takes another step toward its strategic ambition to become a global biopharmaceutical company.
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.152 billion euros in 2017, Servier employs 21,700 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.
 ONCASPAR® (pegaspargase). Servier owns the worldwide rights to Oncaspar.
 ONIVYDE® (pegylated liposomal irinotecan). Servier owns the rights to Onivyde outside the United States and Taiwan.